Literature DB >> 16462758

Tumorigenic activity of p21Waf1/Cip1 in thymic lymphoma.

E De la Cueva1, I García-Cao, M Herranz, P López, P García-Palencia, J M Flores, M Serrano, J Fernández-Piqueras, J Martín-Caballero.   

Abstract

The cell cycle inhibitor p21Waf1/Cip1 is among the most important mediators of the tumor suppressor p53. However, there is increasing evidence indicating that p21 could favor tumorigenesis in specific cell types. In particular, the absence of p21 delays the development of thymic lymphomas induced either by ataxia-telangiectasia mutated deficiency or by ionizing irradiation. Here, we extend these observations to the context of p53-deficient mice. The absence of p21 results in a significant extension of the lifespan of p53-null and p53-haploinsufficient mice, and this effect can be attributed exclusively to a decrease in the incidence of spontaneous thymic lymphomas. Specifically, despite the occurrence of a variety of tumor types in the context of p53 deficiency, the only tumors that were significantly impaired by the absence of p21 were thymic lymphomas. Moreover, the absence of p21 also delays the incidence of radiation-induced thymic lymphomas in p53-deficient mice. Interestingly, p21-deficient lymphomas have a higher apoptotic rate than p21-proficient lymphomas, and this could be on the basis of the delayed incidence of thymic lymphomas in the absence of p21. Together, our results indicate that p21 plays an oncogenic role restricted to thymic lymphomas that is mechanistically independent of p53 and associated to a lower tumor apoptotic rate.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16462758     DOI: 10.1038/sj.onc.1209432

Source DB:  PubMed          Journal:  Oncogene        ISSN: 0950-9232            Impact factor:   9.867


  33 in total

1.  Expression of p21 protein predicts clinical outcome in DLBCL patients older than 60 years treated with R-CHOP but not CHOP: a prospective ECOG and Southwest Oncology Group correlative study on E4494.

Authors:  Jane N Winter; Shuli Li; Vikas Aurora; Daina Variakojis; Beverly Nelson; Maryla Krajewska; Lijun Zhang; Thomas M Habermann; Richard I Fisher; William R Macon; Mukesh Chhanabhai; Raymond E Felgar; Eric D Hsi; L Jeffrey Medeiros; James K Weick; Edie A Weller; Ari Melnick; John C Reed; Sandra J Horning; Randy D Gascoyne
Journal:  Clin Cancer Res       Date:  2010-04-06       Impact factor: 12.531

2.  Expression of Werner syndrome gene in hypothalamic neurons in physiological aging.

Authors:  E D Bazhanova; I G Popovich; V N Anisimov
Journal:  Dokl Biol Sci       Date:  2014-01-03

3.  Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis.

Authors:  Xiaoyun Cheng; Weiya Xia; Jer-Yen Yang; Jennifer L Hsu; Chao-Kai Chou; Hui-Lung Sun; Shannon L Wyszomierski; Gordon B Mills; William J Muller; Dihua Yu; Mien-Chie Hung
Journal:  Biochem Biophys Res Commun       Date:  2010-10-30       Impact factor: 3.575

Review 4.  Transcription factors and target genes of pre-TCR signaling.

Authors:  Cristina López-Rodríguez; Jose Aramburu; Rosa Berga-Bolaños
Journal:  Cell Mol Life Sci       Date:  2015-02-22       Impact factor: 9.261

5.  Tumor suppressor genes promote rhabdomyosarcoma progression in p53 heterozygous, HER-2/neu transgenic mice.

Authors:  Marianna L Ianzano; Stefania Croci; Giordano Nicoletti; Arianna Palladini; Lorena Landuzzi; Valentina Grosso; Dario Ranieri; Massimiliano Dall'Ora; Ilaria Santeramo; Milena Urbini; Carla De Giovanni; Pier-Luigi Lollini; Patrizia Nanni
Journal:  Oncotarget       Date:  2014-01-15

6.  Suppressor of cytokine signaling 1-dependent regulation of the expression and oncogenic functions of p21(CIP1/WAF1) in the liver.

Authors:  M Yeganeh; Y Gui; R Kandhi; D Bobbala; W-S Tobelaim; C Saucier; A Yoshimura; G Ferbeyre; S Ramanathan; S Ilangumaran
Journal:  Oncogene       Date:  2016-01-04       Impact factor: 9.867

7.  Transgenic mice expressing cyclooxygenase-2 in hepatocytes reveal a minor contribution of this enzyme to chemical hepatocarcinogenesis.

Authors:  Cristina Llorente Izquierdo; Rafael Mayoral; Juana María Flores; Pilar García-Palencia; Carme Cucarella; Lisardo Boscá; Marta Casado; Paloma Martín-Sanz
Journal:  Am J Pathol       Date:  2011-03       Impact factor: 4.307

Review 8.  p21 in cancer: intricate networks and multiple activities.

Authors:  Tarek Abbas; Anindya Dutta
Journal:  Nat Rev Cancer       Date:  2009-06       Impact factor: 60.716

Review 9.  Oncogenic role of p21 in hepatocarcinogenesis suggests a new treatment strategy.

Authors:  Shogo Ohkoshi; Masahiko Yano; Yasunobu Matsuda
Journal:  World J Gastroenterol       Date:  2015-11-14       Impact factor: 5.742

10.  Cyclin-dependent kinase 1 inhibitor RO-3306 enhances p53-mediated Bax activation and mitochondrial apoptosis in AML.

Authors:  Kensuke Kojima; Masaya Shimanuki; Masato Shikami; Michael Andreeff; Hideki Nakakuma
Journal:  Cancer Sci       Date:  2009-03-10       Impact factor: 6.716

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.